In this case, our decision making process used multidisciplinary approach focusing on all possible etiologies of hypertrophic cardiomyopathy (HCM) in paediatrics.1 2 Based on first-line clinical and paraclinical assessments, metabolic disorders (Fabry disease), mitochondrial cardiomyopathies, neuromuscular disease, malformation syndromes, endocrine disorders and drugs or infiltrative diseases (amyloidosis) were least likely diagnoses. [...]we considered only two diagnoses were relevant: HCM associated with sarcomere protein gene mutations3 and leukaemic cell myocardial infiltration. References 1 American College of Cardiology Foundation/American Heart Association Task Force on Practice, American Association for Thoracic Surgery, American Society of Echocardiography, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of cardiology Foundation/American heart association Task force on practice guidelines. J Thorac Cardiovasc Surg 2011; 142: e153–203. doi:10.1016/j.jtcvs.2011.10.020 http://www.ncbi.nlm.nih.gov/pubmed/22093723 2 Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of cardiology (ESC)....

Cardiac abnormality in a prechemotherapy assessment for leukaemia in a 14-year-old girl

10.1136/heartjnl-2020-317031